SGLT2 Inhibitors May Increase Creatinine Clearance: Data Mining Utilizing the FDA Adverse Event Report System Database and Pharmacokinetic Study with Rats
Pharmacology · 25.06.2025 · 110 (5) · 301-308
DOI: 10.1159/000546838 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, online erschienen am 25.06.2025. Verfasst von Yuichi Uwai und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Aichi Gakuin University, Kusumoto, Chikusa, Nagoya, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Creatinine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Augmented renal clearance is a condition in which creatinine clearance exceeds 130 mL/min/1.73 m2. The present study aimed to identify drugs that increase creatinine clearance.
Methods
We initially investigated drugs associated with an upsurge in the reporting frequencies of “creatinine renal clearance increased” (CRCI) and “glomerular filtration rate increased” (GFRI) using the FDA Adverse Event Reporting System (FAERS) database. Effect of the drugs on renal clearance of creatinine and lithium was examined using rats.
Results
The database contained 625 reports on CRCI and GFRI. Among the primary suspect drugs identified, empagliflozin had the highest number of reports (29), followed by canagliflozin (27), emtricitabine/tenofovir (21), and sacubitril/valsartan (21). Dapagliflozin had 16 reports. Reporting odds ratios (95% confidence intervals) for empagliflozin, canagliflozin, and dapagliflozin were 29.7 (20.5–43.1), 28.6 (19.5–42.1), and 19.7 (12.0–32.3), respectively. In rats infused with phlorizin, a typical inhibitor of sodium-glucose cotransporters (SGLTs), increases were observed in fractional glucose excretion, creatinine clearance, and the renal clearance of lithium. The plasma concentration of creatinine remained unchanged, while that of lithium decreased. Renal glucose excretion in rats-administered phlorizin correlated with creatinine clearance (r = 0.859).
Conclusion
These results suggest that SGLT2 inhibitors may increase renal clearance of creatinine or drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Aichi Gakuin University, Kusumoto, Chikusa, Nagoya, Japan.
Zitieren
APA
Uwai, Y., & Nabekura, T. (2025). SGLT2 Inhibitors May Increase Creatinine Clearance: Data Mining Utilizing the FDA Adverse Event Report System Database and Pharmacokinetic Study with Rats. Pharmacology, 110(5), 301-308. https://doi.org/10.1159/000546838
Vancouver
Uwai Y, Nabekura T. SGLT2 Inhibitors May Increase Creatinine Clearance: Data Mining Utilizing the FDA Adverse Event Report System Database and Pharmacokinetic Study with Rats. Pharmacology. 2025;110(5):301-308. doi:10.1159/000546838
BibTeX
@article{Uwai2025,
author = {Uwai, Yuichi and Nabekura, Tomohiro},
title = {SGLT2 Inhibitors May Increase Creatinine Clearance: Data Mining Utilizing the FDA Adverse Event Report System Database and Pharmacokinetic Study with Rats},
journal = {Pharmacology},
year = {2025},
volume = {110},
number = {5},
pages = {301--308},
doi = {10.1159/000546838}
}
EUVIMED